Pacific Biosciences of California, Inc.
PACB· Nasdaq
PACBPacific Biosciences of California, Inc.
Released Feb 12, 2026, after the close
10-K filed Feb 25, 2026, 56 days after period end · 0001299130-26-000034
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $44.65M | $39.22M | $58.36M | $27.35M |
| Net Income | -$40.37M |
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR
| $2.37M |
| -$82.02M |
| -$84.38M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
